Agilent Prices $750M in Senior Notes | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies said last night that it has priced two series of senior notes offerings with an aggregate principal amount of $750 million.

The first series of $250 million in 2.5 percent notes will mature in July 2013. The second series of $500 million in 5 percent notes will mature in July 2020.

Agilent expects to close the offering on July 20.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.